Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
Subscribe To Our Newsletter & Stay Updated